{"blog": [], "keywords": [{"value": "Turing Pharmaceuticals AG", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Shkreli, Martin (1983- )", "name": "persons", "rank": "2", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "House Committee on Oversight and Government Reform", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Securities and Commodities Violations", "name": "subject", "rank": "6", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/01/21/business/dealbook/congress-subpoenas-martin-shkreli-over-drug-prices.html", "document_type": "article", "byline": {"person": [{"lastname": "GOLDSTEIN", "firstname": "Matthew", "role": "reported", "organization": "", "rank": 1}], "original": "By MATTHEW GOLDSTEIN", "contributor": "Andrew Pollack contributed reporting."}, "type_of_material": "News", "multimedia": [{"url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg", "legacy": {"wide": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg", "legacy": {"xlarge": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg", "xlargeheight": "447", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 447}, {"url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "848", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "pub_date": "2016-01-21T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Congress Calls Shkreli to Testify on Rapid Rises in Drug Pricing", "main": "Congress Calls Martin Shkreli to Testify on Rapid Rises in Drug Pricing"}, "print_page": "2", "snippet": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "_id": "569fe66a38f0d80627b20ab9", "slideshow_credits": null, "abstract": "Turing Pharmaceuticals founder Martin Shkreli is served subpoena to appear before House Committee on Oversight and Government Reform to discuss pricing trends and other developments in drug industry; it is unclear whether Shkreli, who has been charged with securities fraud, will show up to testify."}